The battle between US states and the federal power is intensifying as California gets closer to becoming a ‘sanctuary state,’ safe from federal power against cannabis.
The vote took place  just over a week ago, and represented one of the first tangible legal actions taken in the unspoken fight between the states and the federal level when it comes to cannabis. A number of states have moved forward with positive legislation allowing the medical and even recreational use of the drug, while at the federal level the drug is still illegal.
The bill prohibits state or local agencies from providing support to federal causes investigating the “commercial or noncommercial marijuana or medical cannabis activity,” which has been cleared by the State of California.
“The successful Assembly floor vote means the bill has cleared its first house, before today’s deadline, and now heads to the State Senate to be heard by the Senate Public Safety Committee,” Marijuana Industry News wrote.


US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 


The LA Times reported that Assemblyman Reggie Jones-Sawyer, Democrat from Los Angeles, argued the California legislation had to pass since the current administration “threatened to resume enforcement of federal law that considered marijuana an illegal drug.”
During his time on the debate floor, Jones-Sawyer said Bill AB 1578 would make sure resources in the state would not end in the hands of the federal power and used against “individuals and entities that are in compliance with our laws.”
The bill was met with opposition from local Republicans who even called the proposition a violation of federal law. “This is insanity,” Assemblyman James Gallagher said.
Hope for a progressive update to the federal vocabulary on marijuana, slowed down following the appointment of Jeff Sessions as Attorney General, who has called for the return of America’s infamous drug on wars. Sessions also said he “rejects” the concept of cannabis becoming available everywhere.
“Our nation needs to say clearly once again that using drugs will destroy your life,” Sessions said, according to The Independent.

 A new war on drugs

Despite an initial fear of a crackdown on the industry, Sessions’ hands are currently tied, thanks to the bill Republicans were forced to pass in order to fund government up until September. As a result, this, there is no resources for raids against the industry.
“Everybody asks you ‘aren’t you worried about Trump and Sessions shutting the industry down? Most people in the industry went way past that a long time ago,” Scott Boyes CEO of Canadian Bioceutical told the Investing News Network. Boyes also pointed out that Congress won’t want to miss the potential revenue stream provided by cannabis.
However, cannabis consumers in the US have seen dangerous changes due to Sessions. In May, the Attorney General sent a memo to federal prosecutors, asking them to seek the heaviest punishment possible for low-level drug crimes.
This change rolls back the Obama-era policy which had sought a more lax approach to these type of offenses in order to reduce the alarmingly large incarcerated population in the US.
“If you are a drug trafficker,” Sessions said in a speech following the release of the memo, “we will not look the other way. We will not be willfully blind to your misconduct.”

Investor Takeaway

The cannabis industry is causing a ripple across government levels in the US – as liberal states prepare for a large-scale challenge of what increasingly seems to be a return to the war on drugs policy from the Attorney General.
Don’t forget to follow us @INN_LifeScience  and @INN_Cannabis  for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less

Aphria Inc. (” Aphria “, ” we ” or the ” Company “) (TSX: APHA) (NASDAQ: APHA), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life, announced it has closed the accretive, strategic acquisition (the ” Acquisition “) of  SW Brewing Company, LLC (” SweetWater Brewing Company ” or ” SweetWater “), one of the largest independent craft brewers in the United States (“U.S.”) based on volume. Beginning with the flagship 420 beverage offerings, SweetWater has created an award-winning lineup of year-round, seasonal and specialty beers, a portfolio of brands closely aligned with a cannabis lifestyle.

Keep reading... Show less
  • Distinguished economist and former CEO of Ecopetrol, Colombia’s largest corporation and the fourth largest Latin America oil and gas producer included in the Fortune Global 500
  • Internationally recognized advocate for the cannabis industry as a driver of change for the Latam economy
  • Adds proven economic and international business experience to boost the global growth of the Khiron business model
  • Company to discuss Q3 2020 financials and host webcast on Tuesday, December 1 st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announces that Mr. Juan Carlos Echeverry has been appointed to the Board of Directors of the Company, effective immediately. Mr. Echeverry brings extensive corporate, academic and macroeconomic experience, serving as Colombia’s Minister of Finance from 2010 to 2012 and as the CEO and President of Ecopetrol from 2015 to 2017.

Keep reading... Show less

 Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aurora securities between February 13, 2020, and September 4, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/acb .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

Keep reading... Show less